Background and Purpose-Carotid artery stenting may be an economically attractive procedure for hospitals and physicians.
C
arotid artery stenosis is a significant and important cause of ischemic stroke. 1 A recent study found noninferiority between carotid artery stenting (CAS) and carotid endarterectomy (CEA) in average risk asymptomatic patients 2 although comparisons to best medical interventions for primary prevention are lacking. 3 Although Medicare reimbursement for CAS is limited based on certain clinical characteristics, 4 other insurance providers may not have similar restrictions. In addition, reimbursement for CAS may be as much as 30% greater than CEA depending on the clinical circumstance and insurer. 5 Furthermore, CAS can be performed by a variety of interventionalists in surgical fields as well as cardiology, radiology, and neurology-effectively increasing the availability of the procedure. 6 Indeed, rates of surgical management for carotid disease are highest in private-sector fee-for-service, 7 suggesting provider-induced demand (or supply sensitivity). Previous reports suggest that CAS use is highly variable and supply sensitive [7] [8] [9] and has the potential for profitability within dedicated endovascular programs. Given the uncertainty surrounding, the evidence for revascularization in asymptomatic patients-who represent a large majority of those receiving revascularizations in the United States 10 -and the potential for profitability with CAS, we sought to identify the association of hospital ownership (for-profit or nonprofit) on CAS versus CEA utilization for patients admitted to US hospitals for carotid revascularization.
Methods
We conducted a retrospective observational study using the Nationwide Inpatient Sample, 2008 to 2011. We included adult patients with a carotid revascularization procedure during admission (ie, CEA or CAS; Figure 1 . We examined hospital rates of CAS among those receiving carotid revascularization within for-profit compared with nonprofit hospitals. Analyses were performed using descriptive statistics and multilevel multivariable regression to determine the association between hospital ownership and CAS. Sensitivity analyses were performed to investigate the potential effects of the CREST 
Results
Among 600 nonprofit and 123 for-profit hospitals meeting the inclusion criteria, 66 731 carotid revascularizations were performed, 2008 to 2011 ( Figure 1 ). Among these revascularizations, 9989 (15%) were performed within for-profit hospitals (Table I in Figure 2 ).
In total, 18% of CAS were performed in for-profit hospitals, compared with 14% of CEA (P<0.001). After adjustment for patient and hospital characteristics, for-profit hospital ownership was associated with greater odds of CAS for patients undergoing carotid revascularization (adjusted odds ratio, 1.45; 95% confidence interval, 1.07-1.98; Table) .
A sensitivity analysis demonstrated no changes in results pre-and post-CREST or with exclusion of symptom status (Table II in 
Discussion
This study found that for-profit hospital ownership was associated with a higher rate of CAS among carotid revascularizations, 2008 to 2011. Specifically, for every 100 revascularizations, 9 more CAS procedures were performed at for-profit compared with nonprofit hospitals on average. In a multivariable model controlling for available patient and hospital characteristics, for-profit ownership was associated with a 1.4-fold increase in the odds of CAS. Such a discrepancy could have several contributing factors such as patient casemix, varying surgical risk, provider-mix (ie, surgeons versus interventionalists), and potentially, economic incentives.
Uncertainty exists in the utility of carotid revascularization for asymptomatic carotid stenosis compared with contemporary medical interventions alone, and ongoing studies seek to better clarify best treatment options. 10 Despite this uncertainty, CAS use has grown substantially 8 and the large majority of revascularizations are performed on asymptomatic patients. 10 For-profit hospitals may have a greater tendency compared with other types to offer medical services based on profitability. 11, 12 This may incentivize for-profit hospitals to offer more specialized services such as carotid artery stenting programs, which could influence procedure rates. These findings underscore the need to further understand procedural decision making for carotid stenosis and to consider ways to align incentives, such as expanding policies that restrict the use of devices in more controversial clinical settings to clinical trials. 13 Our study has several limitations. We rely on administrative data that may lack granularity and contain inaccuracies. For instance, International Classification of Diseases-Ninth Revision diagnosis codes may have poor specificity for determining asymptomatic versus symptomatic carotid disease, 14 and although we attempted to account for this, we may not be able to completely elucidate accurate symptom status. As a consequence, differences between hospital utilization could be, in part, attributed to differences in unaccounted patient illness. We used a Charlson comorbidity index tailored for stroke outcomes studies in an attempt to adjust for overall disease severity and surgical risk, but this may not embody the full scope of patient illness. Additionally, hospital providermix is unknown, which may confound our results since specialty likely plays a role in therapy decisions.
Despite these limitations, our data suggest that for-profit hospital ownership is associated with greater odds of carotid artery stenting among admissions for carotid revascularization. Further research is needed to understand the individualand system-level factors driving this difference.
